Who Exports Rivaroxaban from India — 221 Suppliers Behind a $52.6M Market
India's rivaroxaban export market is supplied by 221 active exporters who collectively shipped $52.6M across 5,361 shipments. MYLAN LABORATORIES LIMITED leads with a 32.3% market share, followed by DR.REDDY'S LABORATORIES LTD and ZENTIVA PRIVATE LIMITED. The top 5 suppliers together control 58.8% of total export value, reflecting a moderately competitive market structure.
Top Rivaroxaban Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading rivaroxaban exporter from India, holding a 32.3% share of the $52.6M market across 5,361 shipments from 221 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD, ZENTIVA PRIVATE LIMITED, CARITAS HEALTHCARE PRIVATE LIMITED, MICRO LABS LIMITED — collectively control 58.8% of total export value, indicating a moderately concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (32.3%), DR.REDDY'S LABORATORIES LTD (9.9%), ZENTIVA PRIVATE LIMITED (6.1%), CARITAS HEALTHCARE PRIVATE LIMITED (6.0%), MICRO LABS LIMITED (4.5%).
Top Rivaroxaban Exporters from India
Ranked by export value · 221 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED HARMLESS MEDICINES, RIVAROXABAN TAB 10MG30BL FR VIAHARMLESS MEDICINES, RIVAROXABAN TAB 10MG100BL DK/IS/NO VIAHARMLESS MEDICINES, RIVAROXABAN TAB 10MG30BL UK MY | $17.0M | 11 | 32.3% |
| 2 | DR.REDDY'S LABORATORIES LTD APO-RIVAROXABAN 20MG_2X14T ARROTEXARX-RIVAROXABAN 20 TABLETSRIVAROXABANA 20MG TAB 28S | $5.2M | 12 | 9.9% |
| 3 | ZENTIVA PRIVATE LIMITED RIVAROXABAN REDDY 20MG 28S TAB UK NOSRIVAROXABAN BETA 20 MG FILMTABLETTEN 98NOSRIVAROXABAN BETA 15 MG FILMTABLETTEN 98NOS | $3.2M | 2 | 6.1% |
| 4 | CARITAS HEALTHCARE PRIVATE LIMITED RIVAROXABAN 10 MGFINISHED PHARMACEUTICAL PRODUCT - RIVAROXABAN TABLETS 20MGFINISHED PHARAMCEUTICAL PRODUCT RIVAROXABAN TABLET 20MG | $3.2M | 1 | 6.0% |
| 5 | MICRO LABS LIMITED RIVAROXABAN REDDY 20MG 28S TAB UKRIVAROXABAN REDDY 20MG 28S TAB UK 1175720NOS3.5VAROXA 20 TAX INV NO: 701209992/25.03.2025 | $2.4M | 20 | 4.5% |
| 6 | APOTEX RESEARCH PRIVATE LIMITED REDDY RIVAROXABAN TABLETS 2.5MGAPO-RIVAROXABAN FCT 20MG 100 BTL 68679/ 771313254212 VG2010APO-RIVAROXABAN FCT 20MG 500 BTL NOS | $2.3M | 1 | 4.3% |
| 7 | TORRENT PHARMACEUTICALS LTD APO-RIVAROXABAN 20MG_2X14T ARROTEXARX-RIVAROXABAN 20 TABLETSRIVAROXABANA 20MG TAB 28S | $2.1M | 5 | 4.0% |
| 8 | DR REDDYS LABORATORIES LIMITED HARMLESS MEDICINES, RIVAROXABAN TAB 10MG30BL FR VIAHARMLESS MEDICINES, RIVAROXABAN TAB 10MG100BL DK/IS/NO VIAHARMLESS MEDICINES, RIVAROXABAN TAB 10MG30BL UK MY | $1.6M | 5 | 3.1% |
| 9 | INTAS PHARMACEUTICALS LIMITED HARMLESS MEDICINES, RIVAROXABAN TAB 10MG30BL FR VIARIVAROXABAN 10 MGHARMLESS MEDICINES, RIVAROXABAN TAB 10MG100BL DK/IS/NO VIA | $1.6M | 13 | 3.1% |
| 10 | ALEMBIC PHARMACEUTICALS LIMITED APO-RIVAROXABAN 20MG_2X14T ARROTEXARX-RIVAROXABAN 20 TABLETSRIVAROXABANA 20MG TAB 28S | $1.3M | 7 | 2.4% |
| 11 | LUPIN LIMITED APO-RIVAROXABAN 20MG_2X14T ARROTEXARX-RIVAROXABAN 20 TABLETSAPO RIVAROXABAN 20MG 2X14T ARROTEX | $1.2M | 3 | 2.4% |
| 12 | UNISON PHARMACEUTICALS PRIVATE LIMITED RIVAROXABAN REDDY 20MG 28S TAB UKRIVAROXABAN REDDY 20MG 28S TAB UK NOSRIVAROXABAN BETA 20 MG FILMTABLETTEN 98NOS | $1.1M | 6 | 2.1% |
| 13 | AL-SUPREME EXPORTS | $958.3K | 1 | 1.8% |
| 14 | MILAN LABORATORIES (INDIA) PRIVATE LIMITED XABRIVA 20 MG 4X7'SMEDPRALTO 10MG TABLETS 28'SMEDPRALTO 15MG TABLETS 42'S | $853.4K | 1 | 1.6% |
| 15 | DR.REDDY'S LABORATORIES LIMITED APO-RIVAROXABAN 20MG_2X14T ARROTEXARX-RIVAROXABAN 20 TABLETSRIVAROXABANA 20MG TAB 28S | $780.2K | 3 | 1.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Rivaroxaban exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; received FDA warning letter in |
| Micro Labs Limited | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; no FDA warning letters. |
| Torrent Pharmaceuticals Ltd. | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; no FDA warning letters. |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; received FDA warning letter in |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; no FDA warning letters. |
| Lupin Limited | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; no FDA warning letters. |
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; no FDA warning letters. |
| Apotex Research Private Limited | Approved | Yes | Yes | Multiple | FDA-approved with WHO and EU GMP certifications; no FDA warning letters. |
TransData Nexus reviewed the regulatory standing of 8 leading Rivaroxaban exporters from India. 8 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Rivaroxaban sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy's Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a critical center for API manufacturing, which is essential for producing drugs like Rivaroxaban.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses major companies like Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. This region's emphasis on formulations complements the API production in other clusters, facilitating the comprehensive manufacturing of medications such as Rivaroxaban.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a significant export gateway for India's pharmaceutical products. With its well-established infrastructure and proximity to major ports, this region enables efficient distribution of pharmaceuticals to international markets. The presence of numerous pharmaceutical companies in this area underscores its role in the global supply chain for drugs like Rivaroxaban.
4Baddi-Nalagarh — Tax Incentive Zone
Located in Himachal Pradesh, the Baddi-Nalagarh region has emerged as a prominent pharmaceutical manufacturing hub, largely due to favorable tax incentives and government policies. Baddi is home to over 1,000 pharmaceutical manufacturing units, making it one of the largest such clusters in Asia. This region's growth has been instrumental in bolstering India's capacity to produce and export pharmaceuticals, including anticoagulants like Rivaroxaban.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different pharmaceutical clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and production capacities of suppliers, particularly in API manufacturing and formulation development, to ensure consistent quality and supply of Rivaroxaban.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international regulatory standards, such as those set by the USFDA and EMA, to maintain product quality and facilitate smooth export processes.
- Leverage Export Infrastructure: Utilize the logistical advantages of clusters like Mumbai-Thane-Raigad for efficient distribution of Rivaroxaban to international markets.
By strategically sourcing from India's diverse pharmaceutical clusters, companies can enhance the resilience and efficiency of their supply chains for Rivaroxaban.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Rivaroxaban exporters from India
DR.REDDY'S LABORATORIES LTD — Dr. Reddy's partners with Pharmazz for Centhaquine in India
In March 2024, Dr. Reddy's Laboratories partnered with Pharmazz Inc. to bring Centhaquine (Lyfaquin) to India. - IMPACT: This collaboration may enhance Dr. Reddy's portfolio, potentially influencing its Rivaroxaban export strategy.
Impact: This collaboration may enhance Dr. Reddy's portfolio, potentially influencing its Rivaroxaban export strategy.
Common Questions — Rivaroxaban Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which rivaroxaban supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 257 recorded shipments worth $17.0M. DR.REDDY'S LABORATORIES LTD (131 shipments) and ZENTIVA PRIVATE LIMITED (148 shipments) are also established high-volume exporters.
Q How many rivaroxaban manufacturers are there in India?
India has 221 active rivaroxaban exporters with a combined export market of $52.6M across 5,361 shipments to 115 countries. The top 5 suppliers hold 58.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for rivaroxaban from India?
Average FOB unit price: $7.08 per unit, ranging from $0.00 to $1672.11. Average shipment value: $9.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 221 verified Indian exporters of Rivaroxaban ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 5,361 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 115 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5,361 Verified Shipments
221 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists